Paving the critical path of drug development: the CDER perspective

Nat Rev Drug Discov. 2014 Nov;13(11):783-4. doi: 10.1038/nrd4435.


Improving the science of drug development and regulation is important in fulfilling the public health mission of the US Food and Drug Administration (FDA). A decade on from the launch of the Critical Path Initiative, the FDA's Center for Drug Evaluation and Research (CDER) is now participating in more than 20 science-driven consortia to achieve this goal.

MeSH terms

  • Critical Pathways*
  • Drug Approval / methods*
  • Humans
  • United States
  • United States Food and Drug Administration